Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Imaging"
DOI: 10.1186/s40644-018-0136-x
Abstract: BackgroundTo evaluate the effects of long-acting somatostatin analogue (SSA) therapy on 68Ga-DOTA-octreotate (GaTate) uptake at physiological and metastatic sites in neuroendocrine tumour (NET) patients.MethodsTwenty-one patients who underwent GaTate PET/CT before and after commencement of SSA… read more here.
Keywords: pet; long acting; ssa therapy; somatostatin analogue ... See more keywords